What is minimal residual disease (MRD) testing

May 19, 2026Navis AI

Ask Navis about your situation

This answer is general. Get one about your specific case — no signup, answered right here.

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Understanding Minimal Residual Disease (MRD) Testing

Minimal residual disease (MRD) testing is a highly sensitive blood test that detects tiny amounts of cancer cells remaining in your body after treatment—often at levels too small to show up on imaging scans like CT or PET scans.

How It Works

Think of it this way: Standard imaging can detect tumors when they contain millions of cancer cells. MRD testing can detect as few as 1 cancer cell among 1 million normal cells. The test looks for:

  • Cancer DNA fragments in the bloodstream (called "circulating tumor DNA" or ctDNA)
  • Abnormal blood cells (in blood cancers like leukemia and lymphoma)
  • Genetic mutations specific to your cancer

Why Doctors Use MRD Testing

According to NCCN Guidelines and ASCO recommendations, MRD testing helps doctors:

  1. Assess treatment response - Determine if your current treatment is working effectively
  2. Predict outcomes - Undetectable MRD often correlates with better long-term survival
  3. Guide treatment decisions - Results may influence whether to continue, change, or stop treatment
  4. Monitor for recurrence - Detect cancer returning earlier than traditional imaging

What Results Mean

  • MRD-negative (undetectable): No cancer cells detected at the sensitivity level tested—generally a positive sign
  • MRD-positive (detectable): Cancer cells are present, which may prompt treatment adjustments

Important Context

MRD testing is increasingly used in several cancers including:

  • Acute leukemias (ALL, AML)
  • Chronic lymphocytic leukemia (CLL)
  • Multiple myeloma
  • Some solid tumors (breast cancer, colorectal cancer)

However, not all cancers routinely use MRD testing yet, and its clinical significance varies by cancer type.

Questions to Ask Your Doctor

If your care team mentions MRD testing:

  1. Is MRD testing recommended for my specific cancer type?
  2. What will the results tell us about my treatment response?
  3. How will MRD results affect my treatment plan?
  4. How often will I be tested, and when will we get results?
  5. What does it mean if my MRD is positive vs. negative?

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Ask Navis about your case

That answer is general. Ask about your specific situation — no signup, answered right here.

Facing this with someone you love?

Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.

Start a care circle →

Related Questions

Just finished the perspective therapeutics VMT-a-NET phase 1b dosing trial These are the results of my latest PET...

TL;DR: Your latest PET scan shows your cancer is stable—the tumors in your liver are about the same size as before, no new tumors appeared, and the tr

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...

TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya

It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...

TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2